Development and validation of an ELISA with high sensitivity for therapeutic monitoring of afatinib-Reference-Cited by-同舟云学术

Development and validation of an ELISA with high sensitivity for therapeutic monitoring of afatinib

Published:2018-09-01 Issue:18 Volume:10 Page:1511-1523
ISSN:1757-6180
Container-title:Bioanalysis
language:en
Short-container-title:Bioanalysis

Author:

Al-Shehri Mona M¹,El-Gendy Manal A¹,El-Azab Adel S¹,Hamidaddin Mohammed A¹²,Darwish Ibrahim A¹

Affiliation:

1. Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, PO Box 2457, Riyadh 11451, Saudi Arabia

2. Department of Medicinal & Analytical Chemistry, Faculty of Pharmacy, Sana'a University, Sana'a, Yemen

Abstract

Aim: To support the therapeutic drug monitoring of afatinib (AFT), an ELISA was required. Results: A hapten for AFT was prepared and linked to each of BSA and KLH proteins by diazotization/coupling reaction. A polyclonal antibody recognizing AFT with high affinity (IC50 = 40 ng ml-1) was generated and used in the development of a competitive ELISA for quantitation of AFT in plasma samples. The assay limit of detection was 2 ng ml-1. The assay accuracy and precision were proved. Conclusion: The assay is an appropriate alternative to the existing LC–MS/MS assays for AFT and it is anticipated to effectively contribute to the therapeutic drug monitoring of AFT in clinical settings.

Publisher

Future Science Ltd

Subject

Medical Laboratory Technology,Clinical Biochemistry,General Pharmacology, Toxicology and Pharmaceutics,General Medicine,Analytical Chemistry

Link

http://www.future-science.com/doi/pdf/10.4155/bio-2018-0095

Reference29 articles.

1. PubChem. Afatinib dimaleate (2017). https://pubchem.ncbi.nlm.nih.gov/compound/afatinib_dimaleate#section=Top.

2. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

3. The EGF receptor family as targets for cancer therapy

4. Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif™ (afatinib) tablets for oral use. Initial U.S. Approval: 2013 (2017). www.accessdata.fda.gov/drugsatfda_docs/label/2013/201292s000lbl.pdf.

5. Chemocare. Afatinib (gilotrif) chemotherapy drug information (2017). http://chemocare.com/chemotherapy/drug-info/afatinib.aspx.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AFATINIB-A COMPREHENSIVE REVIEW OF ANALYTICAL METHODS DEVELOPED IN PHARMACEUTICALS AND BIOLOGICAL MATRICES;International Journal of Applied Pharmaceutics;2024-07-07

2. Advancements in the preparation technology of small molecule artificial antigens and their specific antibodies: a comprehensive review;The Analyst;2024

3. Preparation and Characterization of Two Immunogens and Production of Polyclonal Antibody with High Affinity and Specificity for Darunavir;Molecules;2020-09-07

4. Development of a highly sensitive ELISA for determination of darunavir in plasma samples using a polyclonal antibody with high affinity and specificity;Bioanalysis;2020-03

5. Development of two different formats of heterogeneous fluorescence immunoassay for bioanalysis of afatinib by employing fluorescence plate reader and KinExA 3200 immunosensor;Scientific Reports;2019-10-14